EcoDrugPlus

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSEEEG00000015258
Gene Symbol: P2RX3A
4 Cross references
194 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3b

Ensembl ID : ENSEEEG00000003581
Gene Symbol: P2RX3B
4 Cross references
201 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 7

Ensembl ID : ENSEEEG00000011426
Gene Symbol: P2RX7
4 Cross references
195 Possible Orthologues:

Purinergic Receptor P2y1

Ensembl ID : ENSEEEG00000007489
Gene Symbol: P2RY1
4 Cross references
191 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSEEEG00000024331
Gene Symbol: P2RY12
4 Cross references
182 Possible Orthologues:

Purinergic Receptor P2y2

Ensembl ID : ENSEEEG00000023463
Gene Symbol: P2RY2
4 Cross references
200 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSEEEG00000012628
Gene Symbol: P2RY4
4 Cross references
168 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSEEEG00000023459
Gene Symbol: P2RY6
4 Cross references
183 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSEEEG00000024174
Gene Symbol: RIPK1L
4 Cross references
198 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSEEEG00000019006
Gene Symbol: RAMP1
4 Cross references
191 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSEEEG00000004779
Gene Symbol: RPTOR
2 Cross references
214 Possible Orthologues:

Renin

Ensembl ID : ENSEEEG00000002172
Gene Symbol: REN
4 Cross references
220 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).